comparemela.com

Latest Breaking News On - ஜோசப் டக்கர் - Page 8 : comparemela.com

COMP SERVICES (CMPS) - Worthy Or Superfluous? Psychedelics Experts Discuss The Sector s Ongoing Patent Debate

The race is continually heating up in the psychedelics space. An array of companies, educational institutions and investors have already obtained patents on formulations, processes, compounds and other aspects of psychedelics treatment. The race has heated to such a degree that certain compounds, like psilocybin, have patent trackers to keep abreast of the market. While exciting, the development of the space creates a discussion around psychedelic patent ethics. In early 2021, COMPASS Pathways PLC (NASDAQ:CMPS) made headlines for its patent applications. Unlike previously granted patents for formulations, Compass applied for patents on commonplace psychedelic experiences, including holding hands and comfortable furniture.

MariMed Inc : MagicMed Industries to present at the Planet MicroCap Showcase: Virtual on April 22nd

MariMed Inc.: MagicMed Industries to present at the Planet MicroCap Showcase: Virtual on April 22nd MagicMed Industries Inc. ( MagicMed or the Company ), a biotechnology company focused on creating novel psychedelic derivative molecules, today announced that Dr. Joseph Tucker, President and Chief Executive Officer, will be presenting a business and pipeline update at the LifeSciencesInvestorForum.com on April 22 nd, 2021 as follows: LINK: https://www.webcaster4.com/Webcast/Page/2059/40839 This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, and archived webcast will also me made available after the event.

Cognistx to Collaborate on AI Initiative to Improve the Development of Psychedelic Medicine for the Treatment of Mental Health Illnesses

Cognistx to Collaborate on AI Initiative to Improve the Development of Psychedelic Medicine for the Treatment of Mental Health Illnesses Share Article Cognistx and MagicMed Industries Inc. will develop PsyAI™, a tool designed to streamline pharmaceutical design in an effort to accelerate the modernization of psychedelic medicines. Cognistx “The convergence of AI and psychedelic medicine will result in a medical renaissance – all to benefit the treatment of mental health conditions,” said Cognistx CEO Sanjay Chopra. “It’s very exciting to be at the nexus of this convergence of medicine with AI technology.” PITTSBURGH (PRWEB) April 09, 2021 Cognistx (Cognistx.com), a tech firm that designs artificial intelligence (AI) business solutions, announces its partnership with MagicMed Industries Inc. (“MagicMed”), a Canadian biotech company, to develop a groundbreaking AI tool (“PsyAI™”) intended

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.